Clinical studies indicate that elevated concentrations of plasma AVP, or its surrogate marker copeptin, are associated with a higher risk of diabetes mellitus and with aggravation of renal and cardiovascular complications of this disease. This evidence concerns the gene AVP and diabetes mellitus.